Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06201234
Status:
RECRUITING
Last Update Posted:
2024-01-11
First Post:
2023-12-07
Brief Title:
Evaluating the Addition of Elacestrant Oral SERD to Olaparib PARP-inhibitor in Patients With AdvancedMetastatic HRHER2- Breast Cancer
Sponsor:
German Breast Group
Organization:
German Breast Group
Organization Data
Organization:
German Breast Group
Class:
OTHER
Study ID:
ELEMENT GBG-114
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
German Breast Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Stemline Therapeutics Inc | OTHER |
| GlaxoSmithKline | INDUSTRY |